US Patent 9550837 Therapeutic uses of anti-PCSK9 antibodies
Patent 9550837 was granted and assigned to Regeneron Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 9550837 Therapeutic uses of anti-PCSK9 antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
